Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: a systematic review and meta-analysis

BACKGROUND: Neoadjuvant therapy has become the standard treatment for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer, with most regimens using a combination of anti-HER2-targeted drugs and chemotherapy. However, the combination of anthracyclines and trastuzumab has high...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jingjin, Min, Ningning, Chen, Yizhu, Li, Xiru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061451/
https://www.ncbi.nlm.nih.gov/pubmed/37007556
http://dx.doi.org/10.21037/atm-22-4030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061451/
https://www.ncbi.nlm.nih.gov/pubmed/37007556
http://dx.doi.org/10.21037/atm-22-4030

Ejemplares similares